Inhibrx (INBX) Competitors

Inhibrx (NASDAQ:INBX) and Pieris Pharmaceuticals (NASDAQ:PIRS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and community ranking.

Is INBX or PIRS more profitable?

Inhibrx has a net margin of 0.00% compared to Pieris Pharmaceuticals' net margin of -39.71%. Pieris Pharmaceuticals' return on equity of -80.93% beat Inhibrx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx	N/A	-113.74%	-80.56%
Pieris Pharmaceuticals	-39.71%	-80.93%	-59.55%

Which has stronger valuation and earnings, INBX or PIRS?

Pieris Pharmaceuticals has higher revenue and earnings than Inhibrx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx	$1.63M	125.08	-$154.96M	N/A	N/A
Pieris Pharmaceuticals	$42.81M	0.52	-$24.54M	-$12.10	-1.39

Do institutionals & insiders hold more shares of INBX or PIRS?

82.5% of Inhibrx shares are owned by institutional investors. Comparatively, 40.1% of Pieris Pharmaceuticals shares are owned by institutional investors. 22.2% of Inhibrx shares are owned by insiders. Comparatively, 6.4% of Pieris Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the MarketBeat Community believe in INBX or PIRS?

Pieris Pharmaceuticals received 247 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 60.30% of users gave Pieris Pharmaceuticals an outperform vote while only 59.62% of users gave Inhibrx an outperform vote.

Company	Underperform	Outperform
Inhibrx	Outperform Votes 31 59.62%	Underperform Votes 21 40.38%
Pieris Pharmaceuticals	Outperform Votes 278 60.30%	Underperform Votes 183 39.70%

Do analysts prefer INBX or PIRS?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pieris Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media refer more to INBX or PIRS?

In the previous week, Inhibrx had 6 more articles in the media than Pieris Pharmaceuticals. MarketBeat recorded 8 mentions for Inhibrx and 2 mentions for Pieris Pharmaceuticals. Inhibrx's average media sentiment score of 1.12 beat Pieris Pharmaceuticals' score of 0.21 indicating that Inhibrx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Pieris Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Inhibrx beats Pieris Pharmaceuticals on 7 of the 13 factors compared between the two stocks.